

GALCANEZUMAB solution for injection (Emgality® ▼) for prophylaxis of migraine

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of GALCANEZUMAB solution for injection (Emgality® ▼) for prophylaxis of migraine

GREY

Galcanezumab is licensed for the prophylaxis of migraine in adults who have at least 4 migraine days per month.¹

This recommendation will be reviewed when the NICE TA is published.

In the meantime, treatment for the prevention of migraine should continue to follow local and national guidance:

- > Pan Mersey Area Prescribing Committee [Headache pathway \(adults\)](#), last updated 26 June 2019.
- > NICE Clinical Guideline [\[CG150\] Headaches in over 12s: diagnosis and management](#), last updated November 2015.
- > British Association for the Study of Headache [Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type, Cluster and Medication-Overuse Headache](#), 3rd edition 2010.

References

1. Eli Lilly and Company Limited. Summary of Product Characteristics: [Emgality 120mg solution for injection in pre-filled pen](#), 21 November 2018. Accessed 25 July 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.